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Dear Editor,
Leclercia adecarboxylata, which is found widely in nature, was ﬁrst isolated
from drinking water and initially described as Escherichia adecarboxylata by
Leclerc in 1962 [1, 2]. The species was renamed after phenotypic and genotypic
studies by Tamura et al. [3] in 1986. It is a motile, facultative-anaerobic, Gram-
negative rod of Enterobacteriaceae family [4]. Several L. adecarboxylata can
be misidentiﬁed as Escherichia coli, because L. adecarboxylata and E. coli
share many biochemical properties [2, 4]. In this report, we aimed to compare
two identiﬁcation systems, VITEK® MS (bioMérieux, France) and VITEK®
2 Compact (bioMérieux), and to evaluate L. adecarboxylata with colony color
on chromogenic CPSE media (bioMérieux) to differentiate L. adecarboxylata
from E. coli, using two clinical isolates deﬁnitively identiﬁed by sequencing of
16S rRNA.
Table I shows general information of two L. adecarboxylata cases. Urine
and pus samples were inoculated on 5% sheep blood agar and MacConkey agar.
Both VITEK® 2 Compact (bioMérieux) automatic identiﬁcation system and
matrix-assisted laser desorption/ionization time of ﬂight mass spectrometry-based
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VITEK® MS system identiﬁed three isolates as L. adecarboxylata, Staphylococ-
cus epidermidis, and Enterococcus faecalis for case 1, and three isolates as L.
adecarboxylata, Enterobacter cloacae, and E. faecalis for case 2. The identiﬁca-
tion of L. adecarboxylata was, additionally, conﬁrmed by 16S rRNA gene
sequencing.
L. adecarboxylata grew as non-hemolytic colonies on blood agar and
lactose-negative (case 1) and lactose-positive (case 2) colonies on MacConkey’s
agar from both of the samples. Pure colonies of L. adecarboxylata isolates were also
inoculated on chromogenic CPSE media. They grew on the chromogenic medium
forming the turquoise green colonies, whereas E. coli isolates usually produced pink
colonies (Figure 1). The antibiotic susceptibility testing was done using VITEK®
2 Compact (bioMérieux). The isolate of case 2 was found susceptible to all the
antimicrobials tested, including ampicillin, cefoxitin, ceftazidime, ceftriaxone,
amikacin, gentamicin, ciproﬂoxacin, trimethoprim-sulfamethoxazole (TMP/SMX),
imipenem, meropenem, ertapenem, piperacillin/ tazobactam, and fosfomisin. The
isolate of case 1 was found susceptible to all the antimicrobials tested except
fosfomycin and TMP/SMX.
L. adecarboxylata has been reported as an uncommon cause of sepsis, septic
arthritis, peritonitis, and diarrhea, and usually isolated as an opportunistic pure
pathogen from clinical specimens including blood, stool, sputum, urine, peritoneal
ﬂuid, and pus in reported cases of immunocompromised patients or patients
with underlying medical conditions [2, 4]. In the immunocompetent patients,
L. adecarboxylata is usually found as a part of polymicrobial infections [4].
This report shows that both of the patients had underlying medical conditions and
demonstrated polymicrobial cultures.
Table I. General information of two Leclercia adecarboxylata cases
Case no. 1 2
Age (years) 5 48
Gender Male Female
Underlying disease Renal atrophy, vesicoureteral reﬂux
operated, and nephrostomy catheter
Stomach cancer
Culture source Urine Pelvic abscess
Co-infection Staphylococcus epidermidis and
Enterococcus faecalis
Enterobacter cloacae and
E. faecalis
Antibiotic resistance Fosfomycin and TMP/SMX None
Colony color on chromogenic
CPSE media
Turquoise green Turquoise green
VITEK® 2 Compact L. adecarboxylata L. adecarboxylata
VITEK® MS L. adecarboxylata L. adecarboxylata
16S rRNA sequencing result L. adecarboxylata L. adecarboxylata
% sequence similarity 98 99
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The accurate identiﬁcation of L. adecarboxylata isolates from clinical
specimens is very important for diagnosis, treatment, and epidemiological infor-
mation. Clinical microbiology laboratories play a key role in the accurate
identiﬁcation of microorganisms, using conventional methods, molecular tests,
and automated systems. Especially technological systems, such as automated
identiﬁcation systems and mass spectrometry, may allow laboratories to identify
unusual organisms rapidly and accurately [5]. In our report, we used VITEK®
MS and VITEK® 2 Compact. Both identiﬁcation systems accurately identiﬁed
L. adecarboxylata isolates. In literature, there are many reports that L. adecar-
boxylata was identiﬁed by automated identiﬁcation systems and mass spectrome-
try [4, 6–10]. However, only two of these reports were conﬁrmed by 16S rRNA
gene sequencing, like our report [9, 10].
Technological systems are quite expensive and may not be available in smaller
laboratories [5]. L. adecarboxylata can be misidentiﬁed as E. coli, because
L. adecarboxylata is phenotypically and biochemically very similar to E. coli that
routine conventional methods may not reliably differentiate them from each other
[2]. Chromogenic CPSE media might be used if automated systems are not available
for identiﬁcation of L. adecarboxylata. Figure 1 shows that it can provide prelimi-
nary information that can be used to differentiate L. adecarboxylata from E. coli.
Stock et al. [2] reported that L. adecarboxylata is naturally resistant to
erythromycin, roxithromycin, clarithromycin, streptogramins, linezolid, penicillin G,
oxacillin, ketolides, lincosamides, glycopeptides, rifampicin, fusidic acid, and
Figure 1. Leclercia adecarboxylata (A) and Escherichia coli (B) colonies on chromogenic CPSE
media
LECLERCIA ADECARBOXYLATA 243
Acta Microbiologica et Immunologica Hungarica 65, 2018
fosfomycin. They also stated that fosfomycin resistance might be useful to
differentiate L. adecarboxylata and E. coli [2]. Despite this knowledge, there
were no information about fosfomycin resistance, or it was not tested in most
of the studies [2–4, 6–10]. One of our isolates was resistant to fosfomycin,
whereas the other was susceptible.
In conclusion, L. adecarboxylata is rarely isolated from clinical specimens
in literature, but usage of new identiﬁcation systems in clinical microbiology
laboratories would increase the prevalence of rare microorganisms, such as
L. adecarboxylata. Besides, in laboratories where automated systems are not
available, chromogenic agar may be useful to differentiate L. adecarboxylata from
E. coli. Additional studies are needed to conﬁrm this information.
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